Vir Biotechnology
Updated: April 10, 2026
CEO - Marianne De Backer
Country: USA | Funding: $1.2B (+)
Founded: 2016
Website: http://www.vir.bio/
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Founded: 2016
Website: http://www.vir.bio/
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
